Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.68 |
| ▸ | TACR3 | P29371 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20181599 | 0.85 | ROCK2 (0.74) | ROCK1ROCK2ADORA3ADORA2AADORA2B | |
| SCHEMBL28955090 | 0.82 | ADORA3 (0.53) | ROCK1ROCK2TACR3ADORA3ADORA2A | |
| SCHEMBL18254900 | 0.81 | ROCK2 (1.00) | ROCK1ROCK2MMEGSK3BRPS6KA3 | |
| SCHEMBL28955091 | 0.76 | ROCK2 (0.51) | ROCK1ROCK2TACR3TP53MAPT | |
| SCHEMBL20181611 | 0.73 | ROCK1 (0.57) | ROCK1ROCK2ADORA3ADORA2AADORA2B | |
| SCHEMBL20181589 | 0.72 | MAPK1 (0.64) | ROCK1ROCK2ADORA3ADORA2AADORA2B | |
| SCHEMBL21787634 | 0.72 | MAPT (0.58) | TACR3ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL20181593 | 0.71 | MAPT (0.58) | ROCK1ROCK2ADORA3ADORA2AADORA2B | |
| SCHEMBL4788746 | 0.71 | GAA (0.75) | MAPTGAAHDAC3HDAC4HDAC1 | |
| SCHEMBL20181396 | 0.70 | ROCK1 (0.78) | ROCK1ROCK2TACR3ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2020-08-13 | — | — | US | disclosed |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2020-08-13 | — | — | US | disclosed |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development (US) | 2020-04-28 | — | — | US | disclosed |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | Translational Drug Development (US) | 2020-04-28 | — | — | US | disclosed |
| EP-3541806-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Translational Drug Development, LLC (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2018-05-24 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-3297437-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016187324-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TD2, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187324-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TD2, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
| US-20180141959-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
| US-10392402-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
| US-10633393-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
| US-20200255448-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK1 67/4885ROCK2 76/4885TACR3 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.